Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy (SHVE)
Primary Purpose
Hepatocellular Carcinoma
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Selective Hepatic Vascular Exclusion
Pringle's Maneuver
Sponsored by

About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring hepatocellular carcinoma, hepatic vein, Surgical resection, occlusion, time to recurrence, overall survival
Eligibility Criteria
Inclusion Criteria:
- Corresponding to diagnostic standards of HCC.
- Patients of liver tumors underwent resection with occlusion of more than one main hepatic veins.
- liver function in the Child-Pugh classification A or B.
- Age between 18~70 years.
- Haven't taken any current treatment.
- Understanding and being willing to sigh the informed consent form.
Exclusion Criteria:
- cannot be follow-up
- severe liver, renal, or brain dysfunction
- with tumor thrombi in the main trunk of portal vein
- with tumor thrombi in the hepatic vein
- with extrahepatic metastasis
Sites / Locations
- Eastern hepatobilliary surgery hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Selective Hepatic Vascular Exclusion
Pringle's Maneuver
Arm Description
Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
Patients with HCC received Pringle's Maneuver in hepatectomy.
Outcomes
Primary Outcome Measures
Overall survival
Secondary Outcome Measures
Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications
Full Information
NCT ID
NCT00820339
First Posted
January 9, 2009
Last Updated
March 30, 2016
Sponsor
Eastern Hepatobiliary Surgery Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00820339
Brief Title
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
Acronym
SHVE
Official Title
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy About Recurrence and Survival :A Prospective Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eastern Hepatobiliary Surgery Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To confirm that SHVE is a safe and effective procedure and it can prevent bleeding of the hepatic vein. To evaluate the recurrence and metastasis in HCC patients undergoing hepatectomy by SHVE.To evaluate that SHVE can improve survival in HCC patients or not.
Detailed Description
Hepatocellular carcinoma (HCC), a serious disease with high incidence at home and abroad still shows a rising trend. In recent decade, the overall survival rate of the disease has entered a platform stage with little advance despite diversified methods of treatment. The prognosis of HCC is not so satisfying.
Intraoperative bleeding remains a major concern during liver resection. Blood loss usually occurs during parenchymal transection and reperfusion after Pringle's maneuver. The amount of blood loss and the need for blood transfusion have a detrimental effect on the short- and long-term prognosis.
Portal triad clamping is sufficient in most situations to control bleeding during hepatectomy. However, it does not prevent backflow bleeding from hepatic veins, which may become troublesome or even hazardous. This is particularly true in tumors that are large or that have invaded into the branches of the major hepatic veins.
SHVE completely isolates the liver from the systemic circulation with the advantage of preventing backflow hemorrhage or air embolism without having to resort to caval blood flow interruption of THVE.
The purpose of the study is to assess the risk factors for the recurrence and metastasis in HCC patients undergoing hepatectomy by SHVE and to evaluate that SHVE can improve survival in HCC patients or not.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
hepatocellular carcinoma, hepatic vein, Surgical resection, occlusion, time to recurrence, overall survival
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
132 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Selective Hepatic Vascular Exclusion
Arm Type
Active Comparator
Arm Description
Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
Arm Title
Pringle's Maneuver
Arm Type
Experimental
Arm Description
Patients with HCC received Pringle's Maneuver in hepatectomy.
Intervention Type
Procedure
Intervention Name(s)
Selective Hepatic Vascular Exclusion
Other Intervention Name(s)
SHVE group
Intervention Description
Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
Intervention Type
Procedure
Intervention Name(s)
Pringle's Maneuver
Other Intervention Name(s)
Pringle's Maneuver group
Intervention Description
Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
Primary Outcome Measure Information:
Title
Overall survival
Time Frame
1,2,or 3 years
Secondary Outcome Measure Information:
Title
Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications
Time Frame
1,2,or 3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Corresponding to diagnostic standards of HCC.
Patients of liver tumors underwent resection with occlusion of more than one main hepatic veins.
liver function in the Child-Pugh classification A or B.
Age between 18~70 years.
Haven't taken any current treatment.
Understanding and being willing to sigh the informed consent form.
Exclusion Criteria:
cannot be follow-up
severe liver, renal, or brain dysfunction
with tumor thrombi in the main trunk of portal vein
with tumor thrombi in the hepatic vein
with extrahepatic metastasis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Feng Shen, M.D.
Organizational Affiliation
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
Eastern hepatobilliary surgery hospital
City
Shanghai
State/Province
Shanghai
Country
China
12. IPD Sharing Statement
Learn more about this trial
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
We'll reach out to this number within 24 hrs